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Axonal degeneration induced by glutamate excitotoxicity
is mediated by necroptosis
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ABSTRACT
Neuronal excitotoxicity induced by glutamate leads to cell death and
functional impairment in a variety of central nervous system
pathologies. Glutamate-mediated excitotoxicity triggers neuronal
apoptosis in the cell soma as well as degeneration of axons and
dendrites by a process associated with Ca2+ increase and
mitochondrial dysfunction. Importantly, degeneration of axons
initiated by diverse stimuli, including excitotoxicity, has been
proposed as an important pathological event leading to functional
impairment in neurodegenerative conditions. Here, we demonstrate
that excitotoxicity-induced axonal degeneration proceeds by a
mechanism dependent on the necroptotic kinases RIPK1 and RIPK3,
and the necroptotic mediator MLKL. Inhibition of RIPK1, RIPK3 or
MLKLpreventskeysteps in theaxonal degeneration cascade, including
mitochondrial depolarization, the opening of the permeability transition
pore and Ca2+ dysregulation in the axon. Interestingly, the same
excitotoxic stimuli lead to apoptosis in the cell soma, demonstrating the
co-activation of two independent degenerative mechanisms in different
compartments of the same cell. The identification of necroptosis as a
key mechanism of axonal degeneration after excitotoxicity is an
important initial step in the development of novel therapeutic
strategies for nervous system disorders.
KEY WORDS: Neurodegeneration, Axonal degeneration,
Excitotoxicity, Necroptosis
INTRODUCTION
Neuronal excitotoxicity has been described as a contributing factor
in several pathologies of the central nervous system (CNS),
including Alzheimer’s disease (AD), Huntington’s disease
(HD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease
(PD), epilepsy, cerebrovascular accidents, ischemia, hypoxia and
mechanical trauma (Mehta et al., 2013). Excitotoxicity takes place
as a result of excessive release of the neurotransmitter glutamate,
which in turn activates a variety of synaptic and extra-synaptic
glutamate receptors in neurons, leading to Ca2+ overload and
neuronal death (Lau and Tymianski, 2010).
As glutamate receptors are expressed in the neuronal soma,
dendrites, axons and terminals (Hosie et al., 2012; Lau and
Tymianski, 2010; Stirling and Stys, 2010), glutamate excitotoxicity
is found in different neuronal compartments. Indeed, it has been
demonstrated that glutamate excitotoxicity leads to neuronal
apoptosis (Ankarcrona et al., 1995), as well as degeneration of
axons and dendrites (Hosie et al., 2012). Importantly, axonal
degeneration is a common feature of neurodegenerative conditions
exhibiting excitotoxicity (Salvadores et al., 2017), including ALS
(Fischer et al., 2004), AD (Adalbert et al., 2009), PD (Tagliaferro
and Burke, 2016) and poly-glutamine disorders (Diprospero et al.,
2004), and can therefore represent a target for neuroprotection
(Coleman and Perry, 2002). Studies in the Wlds mutant mice (a
chimeric protein produced by an in tandem triplication of a gene
containing the complete coding sequence of Nmnat1 and the N-
terminal portion of Ube4b) and Sarm1-null mice, in which axonal
degeneration is strongly delayed, have demonstrated the existence of
a regulated mechanism for axonal degeneration (Conforti et al.,
2014). Moreover, expression of theWlds gene or loss-of-function of
Sarm1 in models of neuropathies and neurodegenerative diseases
have been shown to delay, in some situations, pathological events
and functional deficits (Conforti et al., 2014).
Axonal degeneration – a non-apoptotic programed cell death
mechanism – is characterized by an increase in axonal free Ca2+
released from the endoplasmic reticulum (Villegas et al., 2014),
which triggers the opening of the mitochondrial permeability
transition pore (mPTP) (Barrientos et al., 2011), leading to a
decrease inmitochondrial membrane potential, an increase in reactive
oxygen species (ROS) (Calixto et al., 2012), energetic failure
(Villegas et al., 2014) and activation of proteases that degrade the
axon, including calpains and caspases (Ma et al., 2013). Even though
several steps in the axonal degenerative program have been described,
a common upstream signaling pathway activated by diverse stimuli
leading to degeneration has not yet been identified. Interestingly,
some events in the axonal degeneration cascade, including
mitochondrial dysfunction, ROS production and membrane
permeabilization are commonly associated with necroptosis, a
regulated form of necrotic cell death (Vandenabeele et al., 2010b).
Necroptosis was first described in the context of TNFα receptor 1
(TNFR1; also known as TNFRSF1A) activation by TNFα, a death
ligand that induces necroptosis upon formation of a protein complex
known as the necrosome (Vandenabeele et al., 2010b). Necrosome
formation leads to cell death with cellular and organelle swelling,
mitochondrial dysfunction, chromatin condensation and plasma
membrane permeabilization (Vandenabeele et al., 2010b). It was
later demonstrated that necroptosis can be initiated by a wide variety
of stimuli, including TNFα, lipopolysaccharide, endoplasmic
reticulum stress, viral infection and an increase in intracellular
Ca2+ (Kaczmarek et al., 2013). The canonical necroptotic response
depends on the state of ubiquitylation of receptor interacting kinaseReceived 21 December 2017; Accepted 5 October 2018
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1 (RIPK1) (Brenner et al., 2015). Deubiquitylation of RIPK1, as is
seen upon the absence of RIPK1 ubiquitylases, including cellular
inhibitor of apoptosis 1 or 2 (cIAP1 and cIAP2; also known as
BIRC2 and BIRC3, respectively), or mediated by the activation of
cylindromatosis deubiquitylase (CYLD), promote the association
of RIPK1 with cytosolic protein complexes known as Complex IIa,
IIb or the necrosome, inducing apoptosis or necroptosis depending
on caspase-8 activity (Brenner et al., 2015). Complex IIa and
Complex IIb promote apoptosis through the activation of a
caspase-8 dependent cascade, and the processing and inhibition of
RIPK1 and RIPK3. In turn, necroptosis is induced by the formation
of the necrosome complex, constituted by caspase-8, RIPK1,
receptor-interacting kinase 3 (RIPK3), FAS-associated death
domain (FADD), and the short (FLIPs) or long (FLIPL) isoforms
of the FLICE-like inhibitory protein (also known as CFLAR)
(Brenner et al., 2015). Necrosome activation takes place under
pharmacological, viral or endogenous (FLIPs) caspase-8 inhibition,
triggering RIPK1 auto-phosphorylation, RIPK3 phosphorylation by
phosphorylated RIPK1 (pRIPK1) and MLKL phosphorylation by
pRIPK3. Translocation of pMLKL to the plasma membrane, leads
to the formation of the ‘MLKL channel’, which increases Na+ influx
and subsequent osmotic stress (Chen et al., 2014).
Importantly, necroptosis has been shown to be involved in
neuronal dysfunction in models of pathologies with prominent
axonal degeneration in which glutamate excitotoxicity is also a
contributing factor. Examples include MS (Ofengeim et al., 2015),
ALS (Ito et al., 2016), AD (Caccamo et al., 2017), ischemic brain
damage (Chavez-Valdez et al., 2012; Chen et al., 2018), cortical
trauma (You et al., 2008), spinal cord injury (Wang et al., 2015) and
retinal damage (Dong et al., 2012; Rosenbaum et al., 2010).
Although these data demonstrate the functional involvement of
necroptotic cell death in complex CNS disorders, whether
necroptosis directly participates in axonal and dendrite
degeneration after excitotoxicity remains unknown.
Here, we demonstrate that excitotoxicity-induced axonal
degeneration proceeds by a necroptotic mechanism, which
activates mitochondrial mPTP and Ca2+ dysregulation in the
axonal compartment without the requirement of caspase inhibition.
Surprisingly, neuronal soma degenerates simultaneously through
canonical apoptosis, demonstrating differential death mechanisms
in two cellular compartments under the same pro-degenerative
stimulus. As axonal degeneration has been associated with the early
phases of several neurodegenerative conditions, the participation
of necroptotic-associated pathways reveals novel regulators of the
axonal degenerative cascade, an important step to develop
therapeutic strategies for nervous system disorders.
RESULTS
RIPK1 inhibitors prevent glutamate-dependent RIPK1
phosphorylation and delay neurite degeneration
in hippocampal neurons
The involvement of RIPK1 in neurite degeneration induced by
glutamate excitotoxicity was evaluated in rat embryonic hippocampal
neurons after treatment with necrostatin-1 (nec-1), a well-
characterized RIPK1 inhibitor, and necrostatin-1s (nec-1s), which
presents a higher specificity for RIPK1 (Takahashi et al., 2012).
Cultures of hippocampal neurons were exposed to glutamate (20 µM
for 6 h) or vehicle, as a control, in the presence or absence of nec-1 or
nec-1s (100 µM). After treatment, hippocampal neurons were
immunostained with antibodies for acetylated tubulin (Ac-Tub) and
neurofilament medium polypeptide (NF-M) to evaluate neuronal
morphology and cytoskeleton integrity, respectively, and
counterstained with DAPI to characterize nuclear morphology
(Fig. 1A). After 6 h, glutamate treatment induced the fragmentation
of the cytoskeleton and neurite beading. In addition, glutamate
treatment increased the percentage of cells with neuronal soma
showing condensed nuclei (pyknosis) compared to control conditions
(Fig. 1A; Fig. S1A,B). Quantitative assessment of degeneration using
the neurite integrity index (see Fig. S2A, and Materials and Methods
section) showed that the treatment of hippocampal neurons with
glutamate in the presence of nec-1 (or nec-1s) strongly delayed neurite
degeneration compared to what was seen with glutamate alone after 6
and even 24 h of treatment (Fig. 1A,B; Figs S2A and S3).
Nevertheless, glutamate-induced nuclei condensation was not
prevented by nec-1 or nec-1s (Fig. 1A; Fig. S1A,B). Importantly,
nec-1 and nec-1s alone did not alter neurite or nuclear morphology of
hippocampal neurons (Fig. 1A,B; Fig. S1A,B).
The phosphorylation of RIPK1 has been functionally associated
with RIPK1 activation (Vandenabeele et al., 2010a). To study
whether the observed protective effect of RIPK1 inhibition
over neurite degeneration is related to changes in RIPK1
phosphorylation, the relative levels of phosphorylated RIPK1
(pRIPK1) were evaluated by western blotting, using protein
samples from 7–8 days in vitro (DIV) cultured hippocampal
neurons exposed to glutamate (20 µM glutamate for 1.5 h) or
vehicle, as a control, in the presence or absence of nec-1 (100 µM).
Phosphorylated RIPK1 was resolved from unphosphorylated
RIPK1, by PAGE in the presence of Phostag™ additive (see
Materials and Methods). Compared to control conditions, glutamate
induced a significant increase in the relative levels of pRIPK1
compared to the total levels of RIPK1 (Fig. 1C), and nec-1 prevented
the glutamate-induced changes in the relative amount of pRIPK1
(Fig. 1C). As expected from the observation of the glutamate-
induced neuronal degeneration, lower levels of protein were
observed for RIPK1 and Hsp90 (herein referring to Hsp90α/β), the
last used as a protein loading control (Fig. S2B). Nevertheless, the
relative amount of total RIPK1 remained unaffected by treatments
with glutamate or nec-1 compared to untreated neuronal cultures
after normalization to the Hsp90 protein levels (Fig. S2B).
In equivalent conditions, treatment with glutamate (20 µM
glutamate for 1.5 h) induced an increase in the relative levels of
phosphorylated RIPK3 (pRIPK3; antibody designed against
murine RIPK3 phosphorylated on S232) (Chen et al., 2013)
compared with the vehicle condition in the neuronal culture protein
samples (Fig. 2A). In equivalent neuronal culture lysates, pMLKL
co-immunoprecipitation using RIPK1 as the immunoprecipitation
ligand was performed to evaluate the formation of the necrosome
complex after the glutamate stimuli. Glutamate treatment induced
an increase in the relative amount of co-immunoprecipitated
phosphorylated MLKL (pMLKL; antibody designed against
murine MLKL phosphorylated at S345) (Rodriguez et al., 2016)
compared to the vehicle condition (Fig. 2B), suggesting the
necrosome complex was formed after the excitotoxic stimuli.
Western blotting against IgG was used as a loading control for the
immunoprecipitated samples (Fig. 2B).
To directly assess the effect of glutamate and RIPK1 inhibition
over the activation of necroptotic factors in the axonal compartment,
7–8 DIV cultured hippocampal neurons were exposed to glutamate
(20 µM for 3 h) with or without nec-1s pre-treatment, and
subjected to immunofluorescence staining using an antibody
against pMLKL and TAU1, as an axonal-specific marker
(Fig. 1D). Significantly higher relative levels of pMLKL were
observed in axons from neurons exposed to glutamate compared to
those in the vehicle control condition. The observed increase in
2
RESEARCH ARTICLE Journal of Cell Science (2018) 131, jcs214684. doi:10.1242/jcs.214684
Jo
u
rn
al
o
f
Ce
ll
Sc
ie
n
ce
axonal pMLKL induced by glutamate was prevented by nec-1s
pre-treatment (Figs 1D and 2C). To control for the effects of
glutamate treatment and RIPK1 inhibition over TAU1 axonal
stain, 7–8 DIV cultured hippocampal neurons were exposed to
glutamate (20 µM for 3 h) with or without nec-1s pre-treatment
and immunostained for TAU1 and MAP2 to identify the
somato-dendritic compartment. In vehicle control conditions, a
continuous pattern of TAU1 staining with sporadic TAU1-positive
puncta was obtained (Fig. S1E,F). Glutamate treatment induced an
increase in the mean number of puncta in TAU1-positive axons
(Fig. S1E,F), which is a change that is associated with the neurite
beading process during the progression of axonal degeneration.
Fig. 1. See next page for legend.
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Importantly, RIPK1 inhibition using nec-1s prevented the neurite
beading process induced by glutamate (Fig. S1E,F).
Taken together, the above data show that RIPK1 inhibition
prevents glutamate-induced neurite degeneration. In addition,
glutamate treatment induces an early RIPK1, RIPK3 and
MLKL phosphorylation, together with an increase in pMLKL
co-immunoprecipitation with RIPK1, suggesting that the
necrosome complex is formed upon this treatment.
RIPK3 and MLKL knockdown delay neurite degeneration in
hippocampal neurons exposed to glutamate
RIPK3 and MLKL knockdown by means of shRNA was used to
evaluate the participation of RIPK3 and MLKL in glutamate-
induced neurite degeneration. Cultured hippocampal neurons were
electroporated with a mix of plasmids containing shRNA sequences
designed to knockdown RIPK3 or infected with lentivirus
expressing shRNA to knockdown MLKL expression. The used
shRNA constructs co-express GFP as a reporter gene to identify
electroporated or infected neurons and for subsequent neurite
morphology analysis.
Neurons electroporated with either RIPK3 or scramble shRNA
plasmids were exposed to vehicle or glutamate (20 µM) for 6 h. To
control RIPK3 knockdown in electroporated neurons, protein
samples from cultures of hippocampal neurons were collected and
used for western blotting of RIPK3 and Hsp90, as a loading control
(Fig. 3A, left). Densitometry analysis shows that RIPK3 shRNA-
electroporated neurons expressed significantly less RIPK3 than
neurons electroporated with the scramble shRNA construct
(Fig. 3A, right). Neurons were fixed and immunostained for
Ac-Tub and GFP, together with DAPI for nuclear staining
(Fig. 3B). For quantification of neurite degeneration, neurites of
electroporated neurons were classified as continuous, beaded or
fragmented and the proportion in each class represented as a
percentage of the total analyzed neurites (Fig. 3C). A continuous
morphology is associated with a healthy neurite, and both beaded
and fragmented morphologies represent progressive stages of
degeneration. For neurons electroporated with a scramble shRNA,
glutamate treatment induced a significant increase in the percentage
of fragmented neurites and a significant decrease in continuous
neurites (Fig. 3B,D). In contrast, neurons electroporated with the
RIPK3 shRNA construct were strongly protected from glutamate-
induced neurite beading and fragmentation (Fig. 3B,D). In addition,
glutamate treatment in both scramble and RIPK3 shRNA
electroporated neurons induced a significant increase in the
number of nuclei showing condensed morphology when
compared to vehicle-treated neurons, with a slight, but significant,
reduction of condensed nuclei in neurons electroporatedwith RIPK3
shRNA compared to the scramble electroporated control (Fig. S1C).
Similar results regarding neurite degeneration were seen upon
MLKL knockdown. Cultured hippocampal neurons were infected
with lentiviruses expressing shRNA against MLKL or scramble
sequences. Glutamate treatment (20 μM for 6 h) induced a
significant increase in the percentage of neurites showing beaded
or fragmented morphology compared with the scramble and
shRNA-MLKL vehicle controls (Fig. 3E; Fig. S4). The
knockdown of MLKL protected strongly against glutamate-
induced neurite beading and fragmentation (Fig. 3E; Fig. S4).
RIPK1 inhibition does not prevent glutamate-induced
apoptotic cell death of hippocampal somas
As described above (Figs 1A, 3B; Fig. S1A–C), RIPK1 inhibition
and RIPK3 knockdown do not prevent neuronal death induced
Fig. 1. RIPK1 inhibition delays neurite degeneration in cultured
hippocampal neurons exposed to glutamate, and prevents RIPK1 and
MLKL phosphorylation induced by glutamate. (A) Dissociated 7–8 DIV
cultured hippocampal neurons immunostained for acetylated tubulin (Ac-Tub,
green), neurofilament medium polypeptide (NF-M, red) and DAPI nuclear
staining (blue). Cultures were treated with vehicle or glutamate (20 μM for 6 h)
with or without nec-1 or nec-1s pre-treatment (100 μM for 18 h). Arrows and
arrowheads indicate healthy and condensed neuronal somas, respectively.
Scale bar: 50 μm. (B) Quantification of neurite integrity for immunostained
neurons as in A, using the NF-M mean±s.e.m. neurite integrity index (n=3;
one-way ANOVA). ***P<0.001 compared to the vehicle treatment (Tukey’s
post-test). (C) Left, western blot of RIPK1 from protein lysates from
hippocampal cultures treated with vehicle or glutamate (20 μM for 1.5 h) with
or without nec-1 pre-treatment (100 μM for 18 h). Phosphorylated (pRIPK1)
and non-phosphorylated (RIPK1) bands were visualized using anti-RIPK1
antibody on membranes with proteins transferred from a Phostag™
phosphorylated protein SDS-PAGE shift assay. Right, densitometric (O.D.)
analysis of RIPK1 Phostag™ western blots. The relative amount of pRIPK1
normalized to the total amount of RIPK1 (pRIPK1+RIPK1) is shown as the
mean±s.e.m. (n=3). *P<0.05 compared to the vehicle treatment (one-way
ANOVA with Tukey’s post-test). (D) Top, dissociated 7–8 DIV hippocampal
neuron cultures immunostained for pMLKL (green), TAU1 (red; axonal
immunostain) and DAPI nuclear staining (blue). Cultures were treated with
vehicle or glutamate (20 μM for 3 h) with or without nec-1s pre-treatment
(100 μM for 18 h). Scale bar: 20 μm. Full images of this experiment can
be found in Fig. S2C. Bottom, quantification of the mean±s.e.m. axonal
immunofluorescence intensity of pMLKL (n=3). *P<0.05 compared to the
vehicle treatment (one-way ANOVA with Tukey’s post-test). Quantifications
were made from three independent cultures, each one with three replicates
for each treatment. a.u., arbitrary units.
Fig. 2. Glutamate treatment of cultured hippocampal neurons induces
increases in RIPK3 phosphorylation and pMLKL co-immunoprecipitation
with RIPK1. Dissociated 7–8 DIV cultured hippocampal neurons protein
lysates were collected after vehicle or glutamate (20 μM glutamate, 1.5 h)
treatments and used for western blot analysis of pRIPK3 and pMLKL. (A) Top,
western blot of pRIPK3 and Hsp90 (loading control). Bottom, densitometric
(O.D.) quantification of pRIPK3 mean levels normalized to the Hsp90 levels.
Results are mean±s.e.m. (n=3). *P<0.05 (unpaired, two tailed t-test).
(B) Top, western blot of pMLKL and IgG (loading control) from RIPK1-
immunoprecipitated protein samples. Bottom, densitometric quantification
of pMLKL mean±s.e.m. levels normalized to the IgG mean values (n=3).
**P<0.01 (unpaired, two tailed t-test). The membrane cut site in the IgG
western blot is indicated. Quantifications were made from three independent
cultures, each one with three replicates for each treatment. a.u., arbitrary units.
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by glutamate excitotoxicity. To evaluate which kind of cell death
was induced by glutamate treatment in neuronal somas, where
necroptotic neurite degeneration was observed, TUNEL and
propidium iodide (PI) exclusion assays were used to identify
apoptotic and necrotic cell death, respectively. Together with these
assays, electron microscopy (EM) was also performed in equivalent
treatments, to ultra-structurally discriminate between each type of
cell death. Cultured hippocampal neurons were treated with
glutamate (20 µM for 6 h) with or without nec-1 treatment
(100 µM). Compared to control conditions, glutamate treatment
induced a significant increase in the percentage of TUNEL-positive
neuronal nuclei. Moreover, glutamate treatment did not induce a
significant increase in the percentage of PI-positive nuclei
(Fig. 4A–C). Ultra-structurally, glutamate induced nuclei
condensation in neuronal somas without extensive membrane
breakdown or organelle swelling (Fig. 4A). Nec-1 treatment did
not prevent the increase in the percentage of TUNEL-positive nuclei
and the ultrastructural changes induced by glutamate (Fig. 4A,B),
suggesting that degenerative mechanisms activated by glutamate in
the neuronal soma correspond to an apoptotic cascade that is
independent from RIPK1. Treatment with H2O2 (50 µM for 4 h)
was included as a positive control for the PI exclusion assay, and
causes a significant increase in PI-positive nuclei compared to
control conditions (Fig. 4A,C; Fig. S1D).
Fig. 3. RIPK3 and MLKL knockdown prevent neurite degeneration in hippocampal neurons exposed to glutamate. (A) Left, RIPK3 western blot from
protein lysates of 7–8 DIV hippocampal neuronal cultures electroporated with scramble or shRNA-RIPK3 plasmids (see Materials and Methods). The Hsp90
western blot was used as loading control for both conditions. Right, densitometric analysis (O.D.) of the mean±s.e.m. relative RIPK3 levels normalized to the
Hsp90 values (n=3). **P<0.01 (unpaired, two-tailed t-test). (B) Dissociated hippocampal neurons in culture electroporated with scramble or shRNA-RIPK3
plasmids. Neuronswere immunostained for GFP (green) and Ac-Tub (red) and showDAPI nuclear staining (blue). Cultures were treated with vehicle or glutamate
(20 µM glutamate for 6 h). Stars depict the presence of neurites with a continuous morphology, arrows show beaded neurites and arrowheads fragmented
neurites. Scale bar: 50 µm. (C) Detailed images of GFP-positive neurites with continuous, beaded or fragmentedmorphology. Scale bar: 10 μm. (D) Mean±s.e.m.
percentage of neurites from single neurons that show continuous, beaded or fragmentedmorphology for the treatments described in B (n=3). *P<0.05; ***P<0.001
compared to vehicle treatment in scramble electroporated neurons (one-way ANOVAwith Tukey’s post-test). (D) Mean±s.e.m. percentage of neurites from single
neurons that show continuous, beaded or fragmented morphology for the treatments described in Fig. S4, showing the effects of MLKL knockdown over
glutamate-induced neurite degeneration in 7–8 DIV cultured hippocampal neurons (n=3). *P<0.05; ***P<0.001 compared to vehicle treatment in scramble
electroporated neurons (one-way ANOVA and Tukey’s post-test). Quantifications were made from three independent cultures, each one with three replicates
for each treatment. a.u., arbitrary units.
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Axonal degeneration is prevented by RIPK1 inhibition in the
axonal compartment in glutamate treated neurons
Pharmacological inhibition of RIPK1 or genetic knockdown of
RIPK3 inhibits neurite degeneration but not nuclear apoptosis after
glutamate excitotoxicity, suggesting that different cell death
mechanisms are activated in the soma versus the axon
compartment. To test whether the protective effect of targeting
RIPK1 was specific to the axonal compartment, hippocampal
neurons were grown in microfluidic devices to spatially isolate
axons from neuronal somas. Neurons were seeded in one of the
compartments of each microfluidic device and extending axons
reached the second compartment by crossing microgrooves small
enough to restrain somas from crossing at the step of neuronal
seeding. The maintenance of a higher volume of medium in the
neuronal compartment of the microfluidic device, allowed axonal-
specific treatment owing to the presence of positive hydrostatic
pressure towards the axonal compartment (Fig. 5A). Neurons were
exposed to glutamate treatment (20 µM) for 6 h in the neuronal
compartment of the microfluidic device, and only axons were
treated with nec-1 (100 µM) or vehicle solution by placing the
appropriate solution in the axonal compartment of the microfluidic
device. In these conditions, glutamate treatment induced an increase
in axonal fragmentation as revealed by both Ac-Tub and NF-M
staining (Fig. 5B), and a significant decrease in the axonal integrity
index (Fig. 5C). Treatment of axons with nec-1 prevented the
fragmentation induced by glutamate treatment (Fig. 5B,C).
Importantly, nec-1 treatment in the absence of glutamate did not
produce noticeable effects in neurite morphology compared to
control conditions (Fig. 5B,C). Taken together, these results suggest
that axonal degeneration induced by neuronal excitotoxicity can be
prevented by inhibiting RIPK1 in the axonal compartment.
Glutamate-induced mitochondrial dysfunction in neurites is
prevented by RIPK1 inhibition
Axonal degeneration after mechanical damage is associated with
mitochondrial dysfunction, including a decline in mitochondrial
Fig. 4. RIPK1 inhibition does not prevent apoptotic neuronal death in cultured hippocampal neurons exposed to glutamate. (A) 7–8 DIV
hippocampal neuron cultures subjected to assays as follows. 1st and 2nd columns: TUNEL assay [TUNEL stain (green), Hoechst 33342 stain (blue), AcTub
immunostain (red)]. Scale bar: 50 µm. 3rd column (EM): processed for transmission EM. Scale bar: 5 µm. 4th column: live-cell PI exclusion assay (PI, red;
Hoechst 33342, blue). Arrows depict PI-positive nuclei. Scale bar: 100 µm. Cultures were treated with vehicle or glutamate (20 µM for 6 h) treatment with or
without nec-1 pre-treatment (100 µM for 18 h). (B) Mean±s.e.m. percentage of TUNEL-positive neurons for each treatment as shown in A (n=3). ##P<0.01
compared with nec-1 control treatment. ***P<0.001 compared with vehicle treatment (one-way ANOVA, with Tukey’s post-test). (C) Mean±s.e.m. percentage
of PI-positive neurons for each treatment shown in A and Fig. S1D. H2O2 treatment (50 µM for 5 h; Fig. S1D) was included as positive control for necrotic
cell death (n=3). ***P<0.001 compared with vehicle treatment (one-way ANOVA, with Tukey’s post-test). Quantifications were made from three independent
cultures, each one with three replicates for each treatment.
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membrane potential and opening of the mPTP (Barrientos et al.,
2011). In these injured axons, mitochondrial responses are
associated with a rise in the cytoplasmic free Ca2+ levels, which
is also a well-known effect of glutamate-induced excitotoxicity.
Therefore, we evaluated whether inhibition of necroptotic factors
prevents neurite and/or axonal mitochondrial dysfunction
induced by excitotoxicity. We assessed mitochondrial function
using the potential-sensitive probe TMRM and evaluated the
opening of the mPTP by the calcein-cobalt staining method in
live-cells exposed to glutamate with or without nec-1 treatment.
Compared to control conditions, glutamate (20 µM) treatment for
1.5 h induced a decrease in TMRMmean fluorescence of individual
mitochondrion located in neurites of dissociated hippocampal
neuronal cultures and in axonal mitochondria of compartmentalized
hippocampal neuron cultures (Fig. 6). Nec-1 pre-treatment
prevented the change in the frequency distribution of TMRM
fluorescence of neurite mitochondrion induced by glutamate
treatment (Fig. S5A), and the decrease in the mean TMRM
fluorescence induced by glutamate (Fig. 6A,B). In a similar way, the
shRNA mediated knockdown of RIPK3 or MLKL via lentiviruses
prevented the decrease in the TMRM fluorescence induced by
glutamate treatment in neurite mitochondria from GFP-positive
infected neurons (Fig. 6C,D). In compartmentalized cultures
(Fig. 5A), nec-1s treatment in the axonal compartment
significantly prevented the decrease in mean axonal mitochondrial
TMRM fluorescence induced by glutamate treatment at the
neuronal soma (Fig. 6E,F).
The calcein-cobalt staining method was used to evaluate
glutamate effects over mPTP opening at neurite mitochondria.
This method relies on the loss of calcein staining in mitochondria
after mPTP opening (see Materials and Methods). Compared to
control conditions, neurite mitochondria exposed to glutamate
exhibited a significant loss of colocalization between Mitotracker-
stained mitochondria and calcein staining (Fig. 7A,B). The
Fig. 5. Axonal RIPK1 inhibition delays axonal degeneration of compartmentalized hippocampal neuron cultures exposed to glutamate in the neuronal
soma. (A) Top left: schematic drawing of the microfluidic device showing the neuronal and axonal compartments. Top right: microscopy picture showing
the detail of the microgroove area and part of the neuronal compartments in a 14–15 DIV hippocampal neuron with compartmentalized culture. Neurons
were immunostained for AcTub (green) and NF-M (red), and with DAPI as a nuclear stain (blue). Arrows depict neuronal soma at the neuronal side of the
compartmentalized culture. Axons span across the microgrooves into the axonal compartment. Scale bar: 50 µm. Bottom left: image of the microfluidic device
with 150 µm microgrooves. Scale bar: 1 cm. (B) Images of the axonal compartment from representative 14–15 DIV compartmentalized cultures subjected to
vehicle or glutamate (20 µM for 6 h) treatment in the neuronal compartment with or without nec1 pre-treatment in the axonal compartment (100 µM for 18 h).
Axons were immunostained for AcTub (green) and NF-M (red), and DAPI nuclear stain was used to show absence of neuronal soma in the axonal compartment.
Scale bar: 50 µm. (C) Axonal integrity quantification for all the treatments described in B, using the axonal integrity index (mean±s.e.m.; n=3), *P<0.05 compared
with vehicle treatment (one-way ANOVA with Tukey’s post-test). Quantifications were made from three independent compartmentalized cultures for each
treatment. a.u., arbitrary units.
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treatment with nec-1 prevented the glutamate-dependent decrease in
colocalization between Mitotracker and calcein (Fig. 7A,B). Other
mitochondrial parameters associated with mPTP activation
are mitochondrial fission and the increase in circularity caused by
mitochondrial swelling. Consistent with mPTP activation, neurite
mitochondrial showed a decrease in their length and an increase in
their circularity after the glutamate treatment (Fig. 7C,D). Nec-1
pre-treatment prevented the morphological parameter changes
induced by glutamate treatment (Fig. 7C,D). Importantly, nec-1
treatment without glutamate did not affect the percentage of
mitochondria showing mPTP opening nor change the mitochondrial
length and/or circularity (Fig. 7).
RIPK1 inhibition prevents axonal Ca2+ dyshomeostasis in
cultured hippocampal neurons after glutamate treatment
The rise in free Ca2+ cytoplasmic levels is a well-known effect of
excitotoxicity induced by glutamate and other pro-degenerative
stimuli in axons, including mechanical damage and chemotherapy-
induced axonal degeneration (Avery et al., 2012; Villegas et al.,
2014). Therefore, we evaluated the effects of RIPK1 inhibition on
Fig. 6. See next page for legend.
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glutamate-dependent changes in Ca2+ dynamics in somas and
neurites of hippocampal neurons. Neurons were loaded with the
Ca2+-sensitive indicator Fura-2, and the effect of glutamate
treatment in the presence or absence of nec-1 was monitored by
time-lapse microscopy. In both neurites and soma, glutamate
(20 µM) induced an immediate rise in the levels of cytoplasmic free
Ca2+ (Fig. 8A,B; Fig. S6A,B). In glutamate-treated neurites, after an
initial rise in cytoplasmic free Ca2+, levels are maintained in a steady
state for ∼30 min; then there is a second phase of Ca2+ rise, known
as delayed Ca2+ dyshomeostasis (DCD), which can be analyzed by
measuring the slope between 30 and 90 min of recording (Fig. 8C).
In nec-1-treated hippocampal neurons, glutamate induced a first
rise of cytoplasmic free Ca2+ in neurites that was comparable to the
changes recorded in neurites from cultures treated with glutamate
only (Fig. 8A,B). Nevertheless, nec-1 treatment significantly
prevented the glutamate-induced DCD (Fig. 8A–C). Because it
has been described that mPTP opening is the point of no return in
axonal degeneration (Barrientos et al., 2011), experiments with the
mPTP blocker CsA were performed to understand the effects of
mPTP opening on neurite Ca2+ dyshomeostasis. In neurites,
treatment with CsA (50 µM) prevented the DCD induced by
glutamate treatment, and the effect was comparable to that seen with
nec-1 treatment in the same excitotoxic conditions (Fig. 8A–C).
Importantly, treatments with vehicle, nec-1 or CsA alone did not
have noticeable effect over the levels of cytoplasmic free Ca2+ for
the whole recording time (Fig. 8A,B). Similar experiments were
performed in compartmentalized cultures to show the specific effect
of RIPK1 inhibition over axonal Ca2+ dyshomeostasis (Fig. 5A).
Axoplasmic free Ca2+ levels at 0, 30, 60 and 90 min were recorded
by taking snapshots of fields with axons charged with the non-
ratiometric Ca2+ probe fluo4. Addition of glutamate (20 µM) to
the neuronal compartment of the microfluidic device induced
a progressive and significant increase in the axoplasmic free
Ca2+ levels that was evident after 90 min of glutamate treatment
(Fig. 8D,E; Fig. S6C). Inhibition of RIPK1 with nec-1s prevented
the glutamate-induced increase of axoplasmic free Ca2+ levels at 90
min compared with that seen in the 0, 30 and 60 min snapshots.
Vehicle and nec-1s controls had no significant effect on the
axoplasmic free Ca2+ levels at the times of the different snapshots
(Fig. 8E; Fig. S6C).
In somas, glutamate induced a fast rise in cytoplasmic free
Ca2+ levels that decayed with time, and that never reached
basal cytoplasmic free Ca2+ levels during the recording time
(Fig. S6A,B). Nec-1 treatment only had a transient effect over the
glutamate-induced neuronal soma free Ca2+ dynamics, causing a
decrease in the amplitude of the cytoplasmic free Ca2+ rise in the
first few minutes after glutamate treatment, but thereafter the levels
of cytoplasmic free Ca2+ were comparable to those in the glutamate
alone treatment during the recording time (Fig. S6A,B). Vehicle and
nec-1 control treatments showed steady basal levels of cytoplasmic
free Ca2+ during the recording time (Fig. S6C).
DISCUSSION
Neuronal degeneration triggered by excitotoxicity leads to the loss
of nervous system function in a variety of neurodegenerative
conditions. Nevertheless, beyond neuronal cell death, the
mechanism by which excitotoxicity led to the degeneration of
axons remained unknown. Degeneration of neuronal extensions has
been intensively studied as a critical degenerative process during
early stages of neurodegeneration. The identification of several
proteins that modify the course of axonal degeneration, including
Wlds, CypD, SARM1 and Axed (Barrientos et al., 2011; Coleman
and Freeman, 2010; Neukomm et al., 2017; Osterloh et al., 2012),
and their conserved function in distant organisms, including worms
(Calixto et al., 2012), flies (Avery et al., 2012) and vertebrates
(Vargas et al., 2015), suggests an evolutionary conserved and
therefore crucial function for axonal degeneration in adult
organisms. Our results suggest that glutamate-induced axonal
degeneration occurs through necroptosis mediated by the activation
of RIPK1, RIPK3 and MLKL, and executed through a Ca2+- and
mPTP-dependent mechanism, which has been previously
implicated in Wallerian degeneration (Barrientos et al., 2011;
Villegas et al., 2014).
Inhibition of RIPK1 and knockdown of RIPK3 and MLKL in
cultured hippocampal neurons delayed glutamate-induced neurite
degeneration without inhibiting apoptosis of neuronal somas. These
results are consistent with studies in other models of neuronal
degeneration showing that soma and neurite degeneration are
controlled by different degenerative mechanisms (Ikegami and
Koike, 2003).
Necroptosis, through the activation of RIPK1 and RIPK3, has
been shown to mediate loss of nervous system function in several
pathologies, including those associated with secondary excitotoxic
damage (Chavez-Valdez et al., 2012; Liu et al., 2014a). Loss of
axons and dendrites correspond to early and common features of
most of these animal models of neurodegenerative conditions
(Lingor et al., 2012); therefore, a common mechanism associated
with neuronal dysfunction in these pathologies might correspond
to necroptotic-dependent axonal degeneration. Furthermore, some
experimental evidence suggests that neuronal apoptosis could be
secondary to axonal loss (Ikegami and Koike, 2003).
Fig. 6. RIPK1, RIPK3 andMLKL inhibition prevents the glutamate-induced
decrease in mitochondrial potential observed in axonal and neurite
mitochondria. (A) Live-cell imaging of neurite mitochondrion from dissociated
7–8 DIV hippocampal neuronal cultures stained with TMRM, a mitochondrial
potential-sensitive dye. Cultures were treated with vehicle or glutamate (20 µM
for 1.5 h) with or without nec-1 pre-treatment (100 µM for 18 h). Scale bar:
2 µm. (B) Mean±s.e.m. relative mitochondrial TMRM fluorescence intensity
for all treatments described in A (n=3). ****P<0.0001 compared with vehicle
treatment (Kruskal–Wallis test with Dunn’s post-test). (C) Neurite mitochondria
from dissociated 7–8 DIV hippocampal neuronal cultures infected with
lentiviruses expressing shRNA against RIPK3, MLKL or a scramble control
sequence and treated with vehicle or glutamate (20 μM for 1.5 h) were stained
with TMRM as a mitochondrial potential reporter. Viral genetic construct
co-express GFP as reporter gene for infected neurons. Left column:
fluorescence of GFP (green) and TMRM (red). Arrowheads depict TMRM-
positive mitochondria in GFP-positive neurites. Arrows show TMRM-positive
mitochondria in GFP-negative neurites. Right column: TMRM intensity profile
images for all the described treatments. Scale bar: 10 μm. Vehicle-treated
controls of neurons expressing shRNA against RIPK3 and MLKL are shown
in Fig. S5B. (D) Mean ±s.e.m. relative mitochondrial TMRM fluorescence
intensity for all treatments described in C (n=3). *P<0.05 comparedwith vehicle
treatment in scramble shRNA expressing neurons (Kruskal–Wallis test
with Dunn’s post-test). For non-compartmentalized culture experiments,
quantifications were made from three independent cultures, each one with
three replicates for each treatment. (E) Axonal mitochondria stained with
TMRM from 14–15 DIV compartmentalized hippocampal neuronal
cultures as shown in Fig. 5A. Cultures were treated with vehicle or
glutamate (20 µM for 1.5 h) in the neuronal compartment, and with or
without nec-1 s pre-treatment in the axonal compartment (100 µM for 18 h).
Scale bar: 2 µm. (F) Mean±s.e.m. relative mitochondrial TMRM fluorescence
intensity for all treatments described in E (n=3). *P<0.05 comparedwith vehicle
treatment (Kruskal–Wallis test with Dunn’s post-test). Color map: relative level
of TMRM fluorescence form less (blue) to high (white) fluorescence intensity.
For compartmentalized culture experiments, quantifications were done from
three independent compartmentalized cultures for each treatment. a.u.,
arbitrary units.
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Several studies in vitro have demonstrated that necroptosis only
becomes activated after caspase inhibition, as caspase-8 is part of the
death complex II, acting as a negative regulator of necroptosis by
cleaving RIPK1 (Vandenabeele et al., 2010b). However, in neurons,
caspase-8 inhibition is not necessary for the engagement of necroptosis
resulting in neuronal cell death (Li et al., 2008). Consistent with this,
our results demonstrate that glutamate-induced RIPK1, RIPK3 and
MLKL activation in neurites occurs in conditions in which caspases
have not been inhibited by experimental interventions, suggesting the
lack of caspase-8 activity or their expression in neurites allows
necroptosis to proceed after glutamate-mediated excitotoxicity.
Moreover, caspase-8 expression is downregulated after oxygen-
glucose deprivation (OGD) or ischemia (Vieira et al., 2014; Xu
et al., 2016), raising another mechanistic explanation for caspase-
independent activation of necroptosis in neurites.
In non-neuronal cells, several stimuli act as necroptotic inductors
through the activation of different signaling transductors, including
TNFR1, TNFR2, CD95R, TRAILR1, TRAILR2, pathogen-
associated molecular pattern (PAMP) receptors, damage-
associated molecular pattern (DAMP) receptors and an increase in
cytoplasmic free Ca2+ (Kaczmarek et al., 2013). In the context of
our studies, a rise in cytoplasmic Ca2+ after glutamate treatment
corresponds to the most plausible explanation for necroptosis
activation. In human SK-N-SH neuroblastoma cells, HVJ-E sendai
virus infection induces RIPK1 phosphorylation and necroptosis cell
death through a Ca2+/calmodulin-dependent protein kinase II
Fig. 7. RIPK1 inhibition preventsmPTPopening andmorphology changes induced by glutamate treatment in neuritemitochondria. (A) Live-cell imaging
of neurite mitochondrion stained with Mitotracker (red; left), calcein (green; center) and colocalization (yellow; right) for the calcein-cobalt mPTP-opening
evaluation assay (see Materials and Methods). Neurons were treated with vehicle or glutamate (20 µM glutamate for 2 h) with or without nec-1 pre-treatment
(100 µM for 18 h). Scale bar: 10 µm. (B) Mean±s.e.m. percentage colocalization between Mitotracker and calcein mitochondrial stains for all the treatments
described in A (n=3). **P<0.01 compared with vehicle treatment and other treatment (one-way ANOVAwith Tukey’s post-test). (C,D) A morphology analysis was
performed in neurites using Mitotracker mitochondrial stain from images as the ones shown in A (left column). Mean±s.e.m. mitochondrial length (C) and mean
mitochondrial circularity±s.e.m. (D), from neurons exposed to vehicle or glutamate (20 µM for 2 h) treatments, with or without nec-1 pre-treatment (100 µM for
18 h) (n=3). **P<0.01, ***P<0.001 compared with vehicle treatment (one-way ANOVAwith Tukey’s post-test). Quantifications were made from three independent
cultures, each one with three replicates for each treatment. a.u., arbitrary units.
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(CaMKII)-dependent mechanism (Nomura et al., 2014). CaMKII is
a broadly expressed kinase in CNS neurons and is a major regulator
of neuronal Ca2+ signaling (Wayman et al., 2008), as well as
glutamatergic excitotoxicity responses (Ashpole and Hudmon,
2011). Therefore, cytoplasmic Ca2+ overload during excitotoxic
stimuli might lead to necroptosis through phosphorylation of RIPK1
after Ca2+-dependent CaMKII activation. Deubiquitylation of
RIPK1 by CYLD leads to necroptosis by activating necrosome
formation (Brenner et al., 2015), and CaMKII-dependent CYLD
activation after NMDA excitotoxicity has been described in
hippocampal neurons (Thein et al., 2014). Therefore, axonal
activation of CaMKII by an increase in cytoplasmic Ca2+ after
glutamatergic excitotoxicity, might directly activate RIPK1 and/or
act indirectly through CYLD.
Fig. 8. See next page for legend.
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Interestingly, it has been shown that activation of RIPK1 and
RIPK3 trigger similar processes during necroptosis in different
cell types (Kaczmarek et al., 2013). For instance, in tumoral
cells, phosphorylation of RIPK3 activates calpains and induces
membrane damage through phospholipase A2-mediated production
of arachidonic acid and lipid hydroperoxidation (Shang et al., 2014;
Sosna et al., 2014). Both calpain activation and phospholipase
A2-mediated membrane degradation has been functionally
associated with axonal degeneration (López-Vales et al., 2008;
Ma et al., 2013; Stys and Jiang, 2002). Also, in tumoral cell lines,
RIPK1 and RIPK3 activity is associated with ROS production
through activation of the NOX1/NADPH oxidase complex,
resulting in oxidative damage (Vandenabeele et al., 2010b).
The increase in the oxidative tone, in turn, causes mPTP
activation, Ca2+ dyshomeostasis, and a further increase in ROS
production and ATP depletion (Görlach et al., 2015). The roles of
Ca2+ dyshomeostasis and oxidative stress have been well
documented during axonal degeneration (Villegas et al., 2014);
therefore, RIPK1 and RIPK3-mediated ROS production and
oxidative damage after an excitotoxic stimuli are likely executors
of neurite degeneration.
RIPK3 activity leads to MLKL phosphorylation. In turn,
phosphorylated MLKL induces Ca2+ overloading and osmotic
stress by mediating opening of Trpm7 channel and the formation of
the ‘MLKL channel’ (Cai et al., 2013; Chen et al., 2014). As both
MLKL and Trpm7 are expressed in neurons (Bae and Sun, 2011;
Liu et al., 2014b), they correspond to possible mediators of
necroptotic Ca2+ dyshomeostasis and plasma membrane breakdown
during axonal degeneration after glutamate excitotoxicity. In
addition, MLKL activation in cell lines leads to mitochondrial
fragmentation and depolarization, mPTP formation and ROS
production, leading to ATP depletion and Ca2+ dyshomeostasis
(Wang et al., 2012).
Our present results show that RIPK1, RIPK3 and MLKL are key
players in a necroptotic-like cascade triggered by glutamate
excitotoxicity leading to neurite degeneration in hippocampal
neurons. Taken together, our results offer a mechanistic explanation
for glutamate-induced axonal degeneration that might contribute
to loss of neuronal function in neurodegenerative conditions
in which the excitotoxic process acts as a primary or secondary
neurodegenerative stimulus. This, in turn, has unveiled novel
therapeutic targets for nervous system disorders. Subsequent studies
will be required to show the possible participation of a similar
necroptotic mechanism in axonal degeneration triggered by other
pro-degenerative stimuli.
MATERIALS AND METHODS
Bioethics
Experiments and animal handling protocols were performed under the
approval of the institutional internal bioethics committee and complied with
National Institutes of Health (NIH) guidelines.
Drugs, reagents, probes and plasmids
Neurobasal™ medium, Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum (FBS), B27® supplement (B-27), GlutaMAX™ I,
penicillin-streptomycin (P/S), 2.5% Trypsin 10×, Hank’s balanced salt
solution (HBSS), Hank’s balanced salt solution with no Ca2+ no Mg2+
(HBSS −Ca2+/−Mg2+), DAPI (358/461 nm), propidium iodide (PI; 535/
617 nm), Hoechst 33342 (Hoechst; 350/461 nm), Fura2-AM (340-380/
510 nm), fluo4-AM (494/516 nm), F-127, tetramethylrhodamine methyl
ester (TMRM; 549/573 nm), calcein-AM (494/517 nm) and Mitotracker
Red CMXRos (Mitotracker; 579/599 nm) were purchased from Thermo
Fisher (Waltham, MA). Paraformaldehyde, poly-L-lysine hydrobromide
(PLL), cytosine β-D-arabinofuranoside hydrochloride (AraC), HEPES,
cold-fish gelatin, Triton X-100, PMSF, protease inhibitor cocktail
P8340 (PIC), L-glutamic acid monosodium salt hydrate (glutamate),
necrostatin-1 (nec-1), cyclosporine A (CsA) and Trypan Blue were
purchased from Sigma-Aldrich (St Louis, MO). Necrostatin-1s (nec-1s)
was purchased from BioVision (Milpitas, CA). pLV-RNAi plasmid
vector with RIPK3 shRNA and scramble sequences were purchased from
Biosettia (San Diego, CA). Fluoromont-G was purchased from Electron
Microscopy Sciences (Hatfield, PA). Phos-tag™ was purchased from
Wako (Osaka, Japan). Non-fat dry milk was purchased from Bio-Rad
(Hercules, CA). Excitation and emission wavelengths are shown in nm for
fluorescent probes.
Primary hippocampal neuron cultures
Hippocampal neurons were obtained from E18 Sprague-Dawley rat
embryos hippocampi using a modified version of the protocol described
by Kaech and Banker (2006). Hippocampi were dissected in ice-cold
HBSS −Ca2+/−Mg2+ (plus 10 mM HEPES, pH 7.3), treated with 0.25%
trypsin, washed in plating medium (5% FBS DMEM) and dissociated using
a fire-polished Pasteur pipettes. Dissociated neurons density and viability
was measured using a Neubauer-improved hemocytometer (Marienfield:
Lauda-Königshofen, Germany) together with Trypan Blue dye exclusion
assay, and seeded at the desired density in 0.5 mg/ml PLL-treated coverslips
(12 or 25 mm, Marienfeld) or plastic dishes (Corning®, Tewksbury, MA)
and maintained in a culture chamber with 5% CO2 and 37°C. After 3 h, the
plating media was changed to Neurobasal™ medium supplemented with
2%B27, 0.5 mMGlutaMAX™-I and P/S. After 3 days, a third of the culture
medium was replaced and treated with 5 µM AraC to inhibit glial cell
proliferation. All experiments were performed with 7 to 8 days in vitro
(7–8 DIV) neurons apart from experiments in microfluidic devices, which
were performed with 14- to 15-day-old cultures (14–15 DIV). All
experiments, with exception of the protein samples for western blots,
microfluidic device and the electroporated cultures, were performed at a
density of 350 cells/mm2.
Fig. 8. RIPK1 inhibition prevents neurite and axonal Ca2+ dys-
homeostasis induced by glutamate treatment in hippocampal neurons
exposed to glutamate. (A) Representative images of neurite fields from fura-2
(free cytoplasmic Ca2+ probe) stained neurites from a live-cell time-lapse
experiment. Images at 1 min (left column), 60 min (center column) and 90 min
(right column) of recordings are shown. Neuronal cultures were treated with
vehicle or glutamate (20 µM at 3 min of recording) with or without nec-1
(100 µM for ∼18 h before the start of time-lapse recording) or CsA (50 µM for
15 min before the start of time-lapse recording) pre-treatments. The color bar
indicates the ratiometric fluorescence intensity of fura-2 from less (blue) to
higher (red) levels. Scale bar: 20 µm. (B) Mean traces of ratiometric fura-2
fluorescence intensity levels from time-lapse recordings obtained from all the
treatments described in A, and including CsA and nec-1 control treatments
(n=3). *P<0.05 compared with glutamate treatment (two-way ANOVA with
Bonferroni’s post-test). (C) Mean±s.e.m. slopes for glutamate, glutamate plus
nec-1 and glutamate plus CsA treatments, between 30 and 90 min of the time-
lapse recordings (n=3). *P<0.05 compared with glutamate treatment (one-way
ANOVA with Tukey’s post-test). Quantifications were performed from three
independent cultures, each one with three replicates for each treatment.
(D) Representative images of compartmentalized cultures loaded with Fluo4
in the axonal compartment treated with vehicle or glutamate (20 µM) in the
neuronal compartment and with or without nec-1s pre-treatment in the axonal
compartment (100 μM for 18 h). Live-cell snapshots of each axonal field in the
axonal compartment were recorded before glutamate treatment (0 min) and
after 60 and 90 min of glutamate treatment. Images from control experiments
are shown in Fig. S6C. The color bar indicates the fluorescence intensity profile
of fluo3 from less (blue) to high (brown) levels. Scale bar: 50 μm. (E) Mean
±s.e.m. fluo4 fluorescence intensity for each treatment at different snap-shot
times. Normalization and statistics for each treatment were performed using
their corresponding mean ‘0 minute’ basal fluorescence as a reference (n=3).
***P<0.001 compared with the respective ‘minute 0’ reference mean
fluorescence value (one-way ANOVA with Tukey’s post-test). For
compartmentalized culture experiments, quantifications were made
from three independent compartmentalized cultures for each treatment.
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Microfluidic devices
Commercial microfluidic devices with 150 µm length microgroove (RD150;
Xona Microfluidics, Temecula, CA), were mounted in 25 mm coverslips
treated with poly-L-lysine as described above (primary hippocampal neuron
cultures) and using the suggested non-plasma bonding protocol provided by
the company. Hippocampal neurons were seeded in plating media at
5×106 cells/ml in the neuronal chamber. The media was changed after three
hours for Neurobasal™ supplemented media that was half changed every
other day for two weeks. To compartmentalize the axonal treatment, two
days before the experiments were performed, a differential volume of media
was placed between the neuronal and the axonal compartments (100 and
80 µl in each well, respectively).
Electroporation
After hippocampal dissociation 106 hippocampal cells were re-suspended
in 100 µl free-serum plating medium plus 100 µg of DNA plasmid
construct and placed in electroporation cuvettes (2 mm gap; NEPAGENE,
Chiba, Japan). The impedance for each electroporation cuvette preparation
was adjusted to between 30 and 40 Ω by serum-free medium addition
and then subjected to three positive polarity poring pulses (275 V,
2 ms duration, 10 ms decay) separated each one by 50 ms, and five
consecutive alternating polarity transfer pulses (20 V, 50 ms duration, 40 ms
decay) with each one separated by 50 ms, using a NEPA21 Super
Electroporator (NEPAGENE). After electroporation, each preparation was
re-suspended in fresh plating medium and seeded on six 25 mm coverslips
previously treated with poly-L-lysine and maintained for regular
hippocampal neuron cultures as described above (primary hippocampal
neuron cultures). The electroporation efficiency was ∼30–40%.
The four plasmids for shRNA and one scramble sequences for RIPK3
knockdown and, control respectively, were designed by Biosettia (San
Diego, CA) using the Rattus norvegicus Ripk3 mRNA sequence (NCBI
reference sequence NM_139342.1) and placed in a pRNAi vector that
co-express GFP as a reporter gene. Ripk3 gene shRNA oligonucleotide
sequences were: 5′-AAAAGGAAAGGCTTCTAAAGCAATTGGATCC
AATTGCTTTAGAAGCCTTTCC-3′, 5′-AAAAGGAAGCATCATTTGG
GCATTTGGATCCAAATGCCCAAATGATGCTTCC-3′, 5′-AAAAG
GAAGAAACAGCAATCCTTTTGGATCCAAAAGGATTGCTGTTTCT
TCC-3′ and 5′-AAAAGCCTACAGTCTATTGTCTTTTGGATCC
AAAAGACAATAGACTGTAGGC-3′. The scrambled sequence was
5′-AAAAGCTACACTATCGAGCAATTTTGGATCCAAAATTGCTCG
ATAGTGTAGC-3′. Underlined parts of the sequences highlight the siRNA
sequence for each oligonucleotide RNA. For RIPK3 shRNA electroporation,
a mix with equal parts of the four shRNA plasmid vectors were used.
Virion production and lentivirus transduction
Human embryonic kidney 293T cells (ATCC) were transfected into 15 cm2
dishes using the CaCl2 (1.25 M)method. Themediumwas replaced 4 h after
the initial transfection, and 48 h later lentivirus-enriched medium were
collected and cleared by slow speed centrifugation at 500 g for 5 min.
Subsequently, the conditioned medium was filtered through a 0.45-μm
pore conic tube filter. The lentiviruses were concentrated using the
Lenti-X-concentrator™ reagent (Clontech, Mountainview, CA) and then
stored at −80°C.
Hippocampal neuron primary cultures were infected 3 h after the
neuronal seeding step with 1:10 dilution of shRNA-expressing lentivirus
mix in supplemented neurobasal medium.
The four plasmids for lentiviral transduction of RIPK3 shRNA, were
designed by Biosettia using the Rattus norvegicus Ripk3 mRNA sequence
(NCBI reference sequence NM_139342.1) and cloned in a pLV-RNAi
vector that co-expresses GFP as a reporter gene. The ripk3 shRNA
oligonucleotide vector used sequences are: 5′-GAAAGGCTTCTAAAG-
CAA-3′, 5′-GAAGCATCATTTGGGCAT-3′, 5′-GAAGAAACAGCAAT-
CCTT-3′ and 5′-CCTACAGTCTATTGTCTT-3′. One plasmid for lentiviral
transduction of MLKL shRNA was designed and packaged by Vigene
Bioscience using the Rattus norvegicus MLKL mRNA sequence (NCBI
reference sequence XM_008772571.2) and cloned in a pLV-RNAi vector
that co-expresses GFP as a reporter gene. TheMlkl shRNA oligonucleotide
vector used sequences 5′-GACCAAACTGAAGACAAATAA-3′ and
5′-TCCCAACATCCTGCGTATATT-3′. One plasmid for lentiviral
transduction of scramble shRNA was designed Vigene Bioscience/and
cloned in a pLV-RNAi vector that co-expresses GFP as a reporter gene.
Immunofluorescence staining
Coverslips were washed twice with 1× PBS solution at room temperature,
fixed in 4% paraformaldehyde for 15 min, washed three times with 1× PBS
for 5 min, and placed in blocking-permeabilizing solution (BP; 5% cold-fish
gelatin and 0.1% Triton X-100) for 1 h. Primary antibody incubations were
performed overnight in the same BP solution. After three 15 min washing
steps using 1× PBS, secondary antibodies were diluted in BP solution and
incubated for 1 h followed by three 15 min washing steps using 1× PBS.
Each immunofluorescence preparation was mounted after a fast washing
step using tri-distillated water in Fluoromont-G with the addition of 3 µM
DAPI for some preparations. The antibodies used and dilutions were as
follows: mouse anti-acetylated tubulin (AcTub; 1:1000; cat. no. T7451;
Sigma-Aldrich), chicken anti-neurofilament medium polypeptide (NF-M;
1:1000; cat. no. AB1987; Merck-Chemicon), rabbit anti-GFP (GFP; 1:500;
cat. no. A-6455; Thermo Fisher), rabbit anti-phospho-(S345)-MLKL
(pMLKL; 1:500; cat. no. ab196436; Abcam: Cambridge, MA), mouse
anti-TAU1 (1:500; cat. no. mab3420; Millipore, Burlington, MA), rabbit
anti-MAP2 (MAP2; 1:1000; cat. no. ab5622; Millipore), goat anti-mouse-
IgG conjugated to Alexa Fluor 488 (1:1000; Thermo Fisher), goat anti-
rabbit alexa 488 (1:1000; Thermo Fisher), goat anti-rabbit-IgG conjugated
to Alexa Fluor 546 (1:1000; Thermo Fisher); goat anti-chicken-IgG
conjugated to Alexa Fluor 594 (1:1000), donkey anti-mouse-IgG
conjugated to Alexa Fluor 594 (1:1000; Thermo Fisher). Images were
acquired in an Olympus IX81-DSU microscope (Olympus: Shinjuku,
Tokyo, Japan) equipped with an Orca-R2 camera (Hamamatsu: Hamamatsu
City, Shizuoka, Japan) and Xcellence software (Olympus). Image
quantification was made using the ImageJ software (NIH, Bethesda, MD).
Neurite and axonal integrity index
Neurite integrity index quantification was made to evaluate the amount
of damage over the NF-M cytoskeleton using images acquired with
100× (regular culture) or 60× (microfluidic culture) objectives. All
NF-M immunofluorescence images were processed simultaneously for
each experiment using ImageJ, to generate binarized masks that were
subjected to particle analysis using filters of 0.3 µm2 for noise signal
elimination (Fig. S2A). Particles with 25 µm2 or lower area and a circularity
index of 0.8 or more were considered as degenerated neurites as they
correspond to NF-M-positive neurite fragments. Particles with values higher
than 25 µm2 of area and a circularity index of 0.8 or less were classified as
non-degenerated NF-M-positive neurites. The neurite integrity index was
quantified as the ratio between the non-degenerated and total NF-M stained
area. The same NF-M image processing and quantification protocol was
used for the axonal integrity index (Fig. 4).
TAU1 puncta quantification
TAU1 puncta quantification was performed by generating a 2000 μm2 grid
(ImageJ) over TAU1 images taken with a 40× objective (Fig. S1E). For each
picture, five random grid-squares with similar axon density were used
for quantification of the number of puncta in 2000 μm2 (Fig. S1F).
Colocalization with MAP2 immunofluorescence stain and DAPI nuclear
stain were used to ignore dendritic neurites and neuronal somas from the
quantification.
TUNEL and PI exclusion assays
The TUNEL assay was performed using the Click-iT® TUNEL Alexa
Fluor® 488 Imaging Assay (Thermo Fisher) according to manufacturer’s
protocol for fluorescence microscopy. Simultaneous TUNEL and
immunofluorescence staining for AcTub was performed according to the
protocol provided. Images were acquired using an Olympus IX81-DSU
microscope. Image processing and quantification were performed using
ImageJ. For the PI exclusion assay, live-cell hippocampal neuronal cultures
were washed twice with HBSS (10 mM HEPES, pH 7.42) and exposed to
the same HBSS solution plus 1 µMHoechst 33342 (Thermo-Fisher, cat. no.
H1399) and 15 µM PI for 20 min at 37°C. Samples were washed twice and
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mounted in a Chamlide® (Live Cell Instrument, Nowon gu, Seoul, Korea)
recording chamber in HBSS. Live-cell snapshot images were acquired using
an Olympus IX81-DSU microscope. Image processing and quantification
were made using the ImageJ software.
Electron microscopy
Hippocampal neuronal cultures seeded in plastic dishes were washed twice
with 1× PBS at 37°C, and fixed in 3% glutaraldehyde (Sigma-Aldrich)
diluted in sodium cacodylate buffer (50 mM sodium cacodylate, pH 7.3;
Sigma-Aldrich) for 2 h at room temperature. Samples were post-fixed in 3%
potassium ferrocyanide diluted in osmium tetra-oxide solution (reduced
for 30 min at room temperature), stained with 2% uranyl acetate solution,
and dehydrated with a gradient of ethanol solutions (30, 50 and 70%) for
5 min each, and finally three times with 100% ethanol for 10 min. The
dehydrated samples were included in epoxy resin and cured at 60°C
overnight. Included samples were added to pre-crafted epoxy resin blocks
and cut in sections of 50–80 nm with an ultra-microtome and mounted on
copper grids. Images were acquired in a TECNAI 12 BIOTWIN
transmission electron microscope (FEI, Hillsboro, OR). Image processing
was undertaken using ImageJ.
Western blotting
Triplicate protein samples from hippocampal neuronal cultures seeded in
plastic dishes at 526 cell/mm2, were collected in ice-cold RIPA buffer
(150 mM NaCl, 50 mM Tris-HCl, 1% NP-40, 0.5% sodium deoxycholate
acid, 0.1% sodium dodecyl sulfate, pH 7.6; Sigma-Aldrich) plus 1 mM
PMSF, PIC and phosphatase inhibitors (1 mM NaF, 5 mM Na3VO4).
All protein samples and processing were managed in EDTA free-buffer
due to incompatibility of EDTA with the PhosTag™ procedure for the
phosphorylated protein mobility shift assay. Protein samples were
centrifuged for 15 min at 14,000 g and 4°C, the soluble fraction was
collected, and the protein concentration was estimated using the BCA
Protein Assay™ (Pierce, Thermo Fisher). Protein samples were diluted in
5× sample buffer, boiled for 5 min and 20 µg of protein were loaded on 10%
SDS-PAGE gels with or without 50 µM Phostag™ and 100 µM MnCl2,
subjected to gel electrophoresis, and then transferred onto PVDF
membranes (Thermo Scientific) for western blotting. For RIPK1 western
blots and before the transference step, all gels were subjected to a 10 min
wash in 1 mM EDTA transfer buffer for Mn2+ elimination, followed by
a 10 min wash in EDTA-free transfer buffer. The membranes with the
transferred proteins were incubated for 1 h in blocking solution (5%
non-fat dry milk and 0.1% Tween 20 in 1× PBS) at room temperature,
incubated overnight at 4°C in primary antibody solution, washed three
times in 1× T-PBS solution (1× PBS with 0.1% Tween 20), incubated
for 1 h in horseradish peroxidase (HRP)-conjugated secondary antibody
solution, washed three times with 1× T-PBS, and revealed using
picogram or femtogram sensitive ECL reactives (Thermo Scientific)
and photosensitive films (Fujifilm, Tokyo, Japan). Primary and
secondary antibodies were diluted in blocking solution and
the dilution used were as follows: mouse anti-RIPK1 (1:400; cat. no.
610459; BD Transduction Laboratories, San Jose, CA), rabbit anti-
phospho-(S345)-MLKL (pMLKL; 1:500; cat. no. ab196436; Abcam,
Cambridge, MA), rabbit anti-phospho-(S232)-RIPK3 (pRIPK3;
1:1000; cat. no. ab195117; Abcam), rabbit anti-RIPK3 (1:200; cat.
no. NBP1-77299, Novus Biologicals), mouse anti-Hsp90 (1:300; cat.
no. sc-7947; Santa Cruz Biotechnology, TX), goat anti-mouse-IgG
conjugated to HRP (1:5000; cat. no. 1706516; Bio-Rad), goat anti-
rabbit-IgG conjugated to HRP (1:10,000; cat. no. 1706515; Bio-Rad).
Thermo Scientific Page Ruler Pre-stained Protein Ladder was used as
molecular mass standard (Thermo Fisher) in all gels with exception of
gels with the Phostag™ additive, where proteins do not migrate
accordingly their molecular mass.
Immunoprecipitation
Immunoprecipitation experiments were performed by incubating 100 μg of
protein with 2.5 μg of anti-RIPK1 (Cell Signaling, Danvers, MA) with
rotation at 4°C for 48 h. Then, 50 μl of protein G magnetic beads (Bio-Rad)
were added to each sample and incubated with rotation at 4°C for 3 h.
Following magnetic separation, beads were mixed with loading buffer and
boiled at 90°C for 5 min. After the elution step, samples were analyzed by
western blotting.
Non-quenching TMRM imaging and mPTP activation assay
For live-cell imaging of mitochondrial potential in neurite mitochondria,
hippocampal neuronal cultures were washed twice with HBSS solution and
treated with 50 nM TMRM diluted in HBSS for 15 min at 37°C. Samples
were mounted in the same 50 nM TMRM HBSS solution in a Chamlide®
recording chamber and subjected to snap-shot image acquisition with an
Olympus IX81-DSUmicroscope. Image processing and quantification were
made using ImageJ software. TMRM experiments in compartmentalized
cultures were performed in equivalent experimental conditions but using a
Leica Dmi8 microscope (Wetzlar, Germany).
mPTP opening was evaluated using the Image-IT™ LIVEMitochondrial
Transition Pore Assay Kit (Thermo Fisher) according to the manufacturer
protocol. Cobalt ion (Co2+) quenches calcein fluorescence, which is only
retained in Co2+ impermeable compartments as mPTP-closed mitochondria.
After mPTP opening, Co2+ enters mitochondria and calcein fluorescence is
quenched in this organelle. Mitotracker is used as mPTP independent
mitochondrial stain and to discard non-mitochondrial calcein staining.
Hippocampal neuronal cultures were washed twice with HBSS solution and
treated in the same solution with 1 µM calcein-AM, 1 mM CoCl2, 200 nM
Mitotracker for 30 min at 37°C. Samples were washed twice with fresh
HBSS, mounted in a Chamlide® recording chamber with HBSS
and subjected to snap-shot image acquisition with an Olympus IX81-
DSU microscope (Olympus). Image processing and quantification were
performed using ImageJ software with a colocalization plugin from Pierre
Bourdoncle (Paris, France).
Ca2+ imaging
For live-cell free intracellular Ca2+ imaging, hippocampal neuronal cultures
were loaded with 1 µM Fura2-AM in HBSS solution plus 0.02% F-127 for
30 min at 37°C. Samples were washed twice and mounted in a Chamlide®
recording chamber with HBSS. Fura2 (at 340 and 380 nm excitation) time-
lapse recordings were acquired for 100 min with 0.5 Hz frequency the first
15 min and with 0.1 Hz for the 85 min left, to record the initial fast and later
slow Ca2+ dynamics induced by the glutamate stimulus, respectively.
Images were acquired, processed for the 340/380 ratio and analyzed with an
Olympus IX81-DSU microscope equipped with an Orca-R2 camera and
Xcellence software. Time-lapse Ca2+ dynamics are shown as averaged time-
lapse traces of neurites (Fig. 8B) or neurons (Fig. S6B). Records were
obtained with from three different cultures (n=3), with three repetitions for
each replicate. Regions of interest (ROIs) were defined in Xcellence
software by drawing by hand following the shape of isolated neurites for the
neurite recordings (Fig. 8A), or using circular shaped ROIs for neuronal
soma recordings (Fig. S6A).
Equivalent procedure was used for experiments in compartmentalized
cultures but using fluo4 as the live-cell free intracellular Ca2+ probe. Axons
in the axonal compartment of each microfluidic device were loaded
with 4 µM solution of fluo4-AM in HBSS solution. Snapshots were taken 1
min before or after 30, 60 and 90 min of glutamate treatment, in the same
field of view for each compartmentalized culture using the
same microscope, camera and light exposure configurations. Each
treatment time point was normalized by the mean time zero fluorescence
value. Images were acquired with a Nikon Ti2-E inverted microscope
equipped with an C2-DU3 3PMT (Nikon, Tokyo, Japan) and NIS-Elements
software. Image processing and quantification were made using ImageJ
software.
Data analysis and statistics
Data analysis and statistics calculations were performed in Prism® software
(Graphpad Software, La Jolla, CA). Data is expressed as mean±s.e.m. n=3
refers to the number of independent cultures made for each experiment, with
exception of experiments in microfluidics devices, where each n refers to
one microfluidic culture. Data were checked for normality (non-significant
Shapiro–Wilk normality test; skewness=−2<0<2; and kurtosis=−7<0<7).
Parametric statistical analyses were performed with a t-test for comparison
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of two treatments, and one-way ANOVA for multiple treatments. Two-way
ANOVA was used for multiple variable analysis in the Ca2+ dynamic
experiments. P<0.05 was considered as significant. Tukey’s and
Bonferroni’s post-test where used for one-way ANOVA and two-way
ANOVA, respectively, for determining differences between groups. Non-
parametric data was analyzed with a Kurskal–Wallis Test. Differences
within groups for non-parametric data were checked with a Dunn’s multiple
comparison test.
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